June 28, 2024 - July 2, 2024

Nephro Care India IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Nephro Care India IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Nephro Care India IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Nephro Care India IPO Review by Dilip Davda (Avoid)

[Dilip Davda] The company is engaged in providing healthcare services with renal insufficiency treatment. It marked inconsistency in its net earnings for the reported periods and the sudden surge in bottom in for 9M-FY24 raise eyebrows and concern over its sustainability going forward. Based on its super annualized FY24 earnings, the issue appears aggressively priced. There is no harm in skipping this pricey bet. Read detail review...

Nephro Care India IPO Peer Comparison

Nephro Care India Limited peer comparison with similar listed entities. (As on March 31, 2023)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Nephro Care India Limited	1.94	1.94	2.44	55.15	79.68	36.89

Nephro Care India IPO Review by Members

Nephro Care India IPO Reviews, analysis and views by popular members. Read Nephro Care India Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Nephro Care India IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%

Member	Review
No recommendation found. Be the first to post the recommendation.

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Comments

Add a public comment...